Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (December 2025)
26 slides from Invo Fertility's investor presentation, December 2025
Slide 1: Life Begins Within – December 2025 Corporate Presentation
LIFE BEGINS WITHIN D E C E M B E R 2 0 2 5 CO R P O R AT E P R E S E N TAT I O N NASDAQ: IVF
Slide 2: Forward-Looking Statements
NASDAQ: IVF F O R W A R D - LO O K I N G S TAT E M E N T S This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this presentation t
Slide 3: Our Mission
OUR MISSION We are a specialty healthcare company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient- centered approach that is powered by innovation, compassion and an exceptional team. 3
Slide 4: Key Highlights: Results, Operating Focus & Market Trends
NASDAQ: IVF KEY HIGHLIGHTS R E S U LT S , O P E R AT I N G F O C U S & MARKET TRENDS REVENUE GROWTH Revenue Growth $7 • Driven by fertility services, including M&A strategy $6.5 $6 Momentum Building Toward Breakeven • Adjusted EBITDA1 loss reduced from approximately -$8.4M in $5 2022 to -$2.2M in 20
Slide 5: Expanding Our Focus in the Fertility Market
NASDAQ: IVF C O M PA N Y E V O L U T I O N E X PA N D I N G O U R F O C U S I N T H E F E R T I L I T Y M A R K E T Beyond our device heritage to a comprehensive healthcare provider + Need different image – to say Fertility center – rather than invocenter Proprietary and novel innovative medical dev
Slide 6: Favorable Macro Trends Providing Tailwinds
NASDAQ: IVF FERTILITY OUTLOOK FAV O R A B L E M A C R O TRENDS PROVIDING TA I LW I N D S Potential to expand access to IVF • ~15% of reproductive-age women are estimated to be experiencing infertility worldwide1 and tap into underserved market • 96 to 186 million represents the estimated global pati
Slide 7: Fertility Centers
NASDAQ: IVF ` FERTILITY CENTERS
Slide 8: Fertility Centers
NASDAQ: IVF FERTILITY CENTERS 800+ CYCLES IN 2024 ACROSS 3 PROPOSED 1 FERTILITY CENTERS ACQUISITION LOCATION Middleton, WI Atlanta, GA Birmingham, AL Indianapolis, IN PROCEDURES IVF, IVC planned IVC, IVF planned IVF and IVC IVF and IVC ANNUAL CYCLES ~500 ~150 ~150 ~200 Profitable; largest contributo
Slide 9: Clinic Revenue Growth
NASDAQ: IVF REVENUE GROWTH CLINIC REVENUE* $8.0 $7.7 $7.0 $6.1 $6.0 $5.0 $4.3 $ Millions $4.0 $3.0 $2.0 $1.7 $1.0 $0.0 2022 2023 2024 9 mos 2025 *Revenue includes both consolidated revenue from Wisconsin Fertility and Atlanta INVO Center, as well as revenue from Birmingham, which is accounted for us
Slide 10: Growth Strategy: Become a Leading Provider of Fertility Services and Technology
NASDAQ: IVF G R O W T H S T R AT E GY BECOME A LEADING PROVIDER OF F E R T I L I T Y S E R V I C E S A N D T E C H N O LO GY ACQUIRE FERTILITY CLINICS ANCILLARY BUSINESSES BUILD NEW CLINICS • Acquire fertility market technologies • Offer IVF+IVC (300+/yr cycles) • Profitable, U.S. IVF clinics with e
Slide 11: Case Study – M&A Strategy: Wisconsin Fertility Institute
NASDAQ: IVF C A S E S T U DY – M & A S T R AT E GY WISCONSIN FERTILITY INSTITUTE Acquisition Details • One of Wisconsin’s leading fertility centers (rated top-100 in US by Newsweek) • 5,000+ babies born since 2007, averaging 500+ IVF cycles/year over the last 5 years • Strong team in place with room
Slide 12: Case Study – New-Build Clinic: Bloom Fertility
NASDAQ: IVF CASE STUDY – NEW-BUILD CLINIC B LO O M F E R T I L I T Y Clinic Details • INVO Center focused primarily on IVC procedure • Approximately 500 IVC cycles since 2022, averaging around 150 cycles/year • Seasoned team in place Growth Details • Add IVF and hire new doctor to expand service off
Slide 13: Advantages: Why Join INVO Fertility?
NASDAQ: IVF A D V A N TA G E S WHY JOIN INVO FERTILITY? Like-Minded Partners; Synergies • Focus on medical practice and patient services, while INVO corporate provides centralized administration, finance, marketing, human resources and other services • Strength in unity – generate synergies to make
Slide 14: Technology
NASDAQ: IVF TECHNOLOGY
Slide 15: Leveraging Technology to Expand Access
NASDAQ: IVF L E V E R A G I N G T E C H N O LO GY TO E X PA N D A C C E S S Medical device heritage Unique INVOcell-enabled IVC procedure improves lab efficiency and capacity, increases fertility service supply and helps to reduce the risk of mix-up occurrences, while providing a more connected pati
Slide 16: INVOcell: Unique Product, Revolutionary Procedure
NASDAQ: IVF INVOcell® U N I Q U E P R O D U C T, R E V O LU T I O N A R Y P R O C E D U R E For clinical pregnancy rates, INVOcell outcomes are comparable to IVF and more effective than IUI. ADVANCED TREATMENT IUI INVOcell (IVC) IVF 8-10%* ~57.1%** ~51.8%** SUCCESS SUCCESS SUCCESS *Fauque P, Lehert
Slide 17: Financials
NASDAQ: IVF FINANCIALS
Slide 18: Income Statement Highlights
NASDAQ: IVF I N C O M E S TAT E M E N T H I G H L I G H T S (USD) FY 2022 FY 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Clinic 614,854 2,862,574 1,537,199 1,807,921 1,418,011 1,687,300 6,450,431 1,621,553 1,832,094 1,722,223 Product 207,342 158,001 39,087 28,676 15,140 -1,3
Slide 19: Balance Sheet Highlights
NASDAQ: IVF BALANCE SHEET HIGHLIGHTS (USD) 12/31/2023 12/31/2024 9/30/2025 Cash and cash equivalents 232,424 619,520 355,891 Other current assets 1,027,351 698,811 780,914 Lease right of use 5,740,929 2,283,784 2,096,739 Intangible assets 4,093,431 3,275,931 1,430,495 Goodwill 5,878,986 5,878,986 5,
Slide 20: Key Information: Stock Data
NASDAQ: IVF S T O C K D ATA K E Y I N F O R M AT I O N INVO Fertility (Nasdaq: IVF) Data as of 12/4/2025* Market capitalization $3.9 million Stock price | 52-week range $1.64 | $0.91 - $299.54 Common shares issued and outstanding 2,386,826 Average volume 1,162,764 * Unless stated otherwise. December
Slide 21: Summary
O)INVvO kertiity NASDAQ: IVF SUMMARY
Slide 22: Why Invest in INVO Fertility? Key Takeaways
NASDAQ: IVF WHY INVEST IN INVO FERTILITY? K E Y TA K E A W AY S Growing Clinic M&A Focus to Drive Integration of Unique Industry Momentum Building Operations Added Growth Technologies Tailwinds Towards Breakeven • Opened INVO Centers • Prioritizing M&A over • Building upon INVOcell • Large supply an
Slide 23: People
NASDAQ: IVF PEOPLE
Slide 24: Leadership Team
NASDAQ: IVF LEADERSHIP TEAM E X P E R I E N C E D & D E D I C AT E D Doctors Steve Shum CEO Gretchen Collins Sue Ellen Carpenter Nick Cataldo James Donahue1 Andrea Goren Terah Krigsvold M&A/Legal Finance/Accounting Lab Directors Prospective Clinic April McGhee Bo Mitrovic Wael Megid Chad Johnson Lis
Slide 25: Board of Directors
NASDAQ: IVF BOARD OF DIRECTORS INDEPENDENT & ENGAGED Steve Shum Trent Davis Rebecca Messina Barbara Ryan Matthew Szot CEO, Director Independent Director Independent Director Independent Director Independent Director December 2025 © 2025 INVO Fertility, Inc. 25
Slide 26: Thank You
THANK YOU For more information, please contact: Steve Shum Andrea Goren 978-878-9505 x506 978-878-9505 x520 sshum@invofertility.com agoren@invofertility.com
INVO Fertility — Investor Presentation (December 2025) on 6ix